Discounted Cash Flow (DCF) Analysis Levered

180 Life Sciences Corp. (ATNF)

$0.6499

-0.04 (-6.41%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Revenue (%)
Operating Cash Flow --------
Operating Cash Flow (%)
Capital Expenditure --------
Capital Expenditure (%)
Free Cash Flow --------

Weighted Average Cost Of Capital

Share price $ 0.6,499
Beta 0.414
Diluted Shares Outstanding 18.15
Cost of Debt
Tax Rate 0.11
After-tax Cost of Debt 4.99%
Risk-Free Rate
Market Risk Premium
Cost of Equity 5.832
Total Debt -
Total Equity 11.80
Total Capital 11.80
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Operating Cash Flow --------
Capital Expenditure --------
Free Cash Flow --------
WACC
PV LFCF --------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 5.83
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -8.22
Equity Value -
Shares Outstanding 18.15
Equity Value Per Share -